# Nephrocare Health Services (NSE: NEPHROPLUS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NEPHROPLUS · Pivot · prices to 22 Oct 2026

Nephrocare Health Services (NSE: NEPHROPLUS) closed at ₹599.90 on 22 Oct 2026, down 0.84% on the day. With a market capitalisation of ₹6,019 Cr, it ranks 728th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 74.1× trailing earnings, against a return on equity of 6.9% in FY26. Its 52-week range is ₹446.00 (19 Dec 2025) to ₹781.50 (11 Sep 2026); the last close is 23.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹266 Cr (+21.2% year on year) and net profit ₹33 Cr (+34.5%), on a consolidated basis. Promoters held 63.85% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹599.90 |
| Market cap | ₹6,019 Cr |
| P/E (trailing) | 74.1 |
| ROE | 6.9% (FY26) |
| ROCE | 13.7% (FY26) |
| Debt to equity | 0.07 |
| 52-week high | ₹781.50 (11 Sep 2026) |
| 52-week low | ₹446.00 (19 Dec 2025) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹266 Cr | +21.2% | ₹33 Cr | +34.5% | ₹3.03 |
| Q3 FY26 | ₹260 Cr | — | ₹32 Cr | — | ₹3.43 |
| Q4 FY25 | ₹219 Cr | — | ₹25 Cr | — | ₹3.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹756 Cr | ₹67 Cr |
| FY24 | ₹566 Cr | ₹35 Cr |
| FY23 | ₹437 Cr | −₹12 Cr |
| FY22 | ₹318 Cr | −₹21 Cr |
| FY21 | ₹286 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.85%
- Foreign institutions: 8.78%
- Domestic institutions: 9.05%
- Non-institutions: 18.32%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | ₹1,504.20 | ₹6,547 Cr | 57.1 | — |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Sun Pharma Advanced Research Company](https://app.pivotnow.in/stock/SPARC) | ₹176.82 | ₹5,738 Cr | 3.7 | — |
| [Senores Pharmaceuticals](https://app.pivotnow.in/stock/SENORES) | ₹1,233.30 | ₹5,680 Cr | 46.7 | — |
| [Innova Captab](https://app.pivotnow.in/stock/INNOVACAP) | ₹983.60 | ₹5,629 Cr | 40 | — |
| [FDC](https://app.pivotnow.in/stock/FDC) | ₹339.20 | ₹5,523 Cr | — | — |

## Questions and answers

### What is the share price of Nephrocare Health Services today?

Nephrocare Health Services (NSE: NEPHROPLUS) last closed at ₹599.90 on 22 Oct 2026. Its 52-week high is ₹781.50 and its 52-week low is ₹446.00.

### What is the market cap of Nephrocare Health Services?

Nephrocare Health Services' market capitalisation is ₹6,019 Cr (₹6,019 Cr) at the 22 Oct 2026 close, ranking 728th among the NSE companies Pivot tracks.

### What is the P/E ratio of Nephrocare Health Services?

Nephrocare Health Services trades at a trailing P/E of 74.1. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.

### What is the ROE and ROCE of Nephrocare Health Services?

Return on equity was 6.9% in FY26 and return on capital employed was 13.7% in FY26 (consolidated figures).

### Is Nephrocare Health Services a debt-free company?

No. Nephrocare Health Services' debt-to-equity ratio was 0.07 in FY26, with total debt of ₹45 Cr.

### What were Nephrocare Health Services' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Nephrocare Health Services reported revenue of ₹266 Cr, +21.2% year on year, and net profit of ₹33 Cr, +34.5% year on year.

### What is the shareholding pattern of Nephrocare Health Services?

As of 30 Jun 2026: promoters 63.85%, foreign institutions 8.78%, domestic institutions 9.05%, non-institutions 18.32%.

### Who are Nephrocare Health Services' competitors?

The listed Pharma & Healthcare companies closest to Nephrocare Health Services by market cap are Entero Healthcare Solutions, Kovai Medical Center & Hospital, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, Innova Captab and FDC.

### Is Nephrocare Health Services a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Nephrocare Health Services' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NEPHROPLUS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.